Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 5/20 | 0.53 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.52 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22234332 | 1.00 | KEAP1 (0.60) | KEAP1NFE2L2NPSR1RXFP1KMT2A | |
| SCHEMBL22252409 | 0.92 | KEAP1 (0.58) | KEAP1NFE2L2NPSR1RXFP1KMT2A | |
| SCHEMBL16088828 | 0.78 | NPSR1 (0.70) | NPSR1RXFP1KMT2AKDM4ECA12 | |
| SCHEMBL29540848 | 0.78 | KEAP1 (0.54) | KEAP1NFE2L2NPSR1RXFP1KMT2A | |
| SCHEMBL22233905 | 0.78 | KEAP1 (0.54) | KEAP1NFE2L2NPSR1RXFP1KMT2A | |
| SCHEMBL9438146 | 0.76 | CA1 (0.73) | NPSR1RXFP1KMT2AKDM4ECA12 | |
| SCHEMBL152663 | 0.73 | KMT2A (0.77) | NPSR1RXFP1KMT2AKDM4E | |
| SCHEMBL4649471 | 0.73 | KMT2A (0.78) | KMT2ACA12CA1CA2CA9 | |
| SCHEMBL22252403 | 0.73 | KEAP1 (0.69) | KEAP1NFE2L2KMT2ASQSTM1EP300 | |
| Lithium Ion SCHEMBL10975499 | 0.73 | CA1 (0.69) | NPSR1RXFP1KMT2AKDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112160-A1 | SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | KEAP1 1/4885NFE2L2 2/4885NPSR1 4562/4885 |
| US-12122742-B2 | Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | KEAP1 1/4885NFE2L2 2/4885NPSR1 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.